Bon Nat Life Ltd (Ticker: BON)

1. Introduction

Bon Nat Life Ltd (NASDAQ: BON) is a US-listed affiliate of Xi’an App-Chem Bio(Tech) Co., Ltd., specializing in plant-based bio-ingredient solutions for food, dietary supplements, cosmetics, and personal care products. The company integrates natural plant extracts with proprietary technologies, supported by independent R&D facilities and multiple quality certifications.

2. Corporate Structure

• Headquarters: US listing; operational base in Xi’an, China
• Affiliation: Xi’an App-Chem Bio(Tech) Co., Ltd. (founded 2006)
• Employee Count: 11–50 (per LinkedIn profile)
• Key Offerings:
  • Natural extracts
  • Health supplement ingredients
  • Fragrance compounds for personal care products
• IP Portfolio: 30+ invention applications; 70+ registered trademarks

3. Developments and News

Extraordinary General Meeting (April 15, 2025)

• Reverse Share Split: One Class A share for every 25 outstanding shares
• Authorized Share Increase:
  • Class A ordinary shares raised to 1 billion
  • Class B ordinary shares raised to 50 million
  • New class of 50 million preference shares
• Vote Results: 204,183,900 votes in favor of each proposal; no votes against or abstentions

Nasdaq Compliance Filings

• April 29, 2025: Notification of non-compliance with minimum bid price ($1.00)
• May 1, 2025: Notice of intent to delist due to bid price ≤ $0.10 over ten trading days and public interest concerns
• By May 6, 2025: Hearing request filed (hearing fee: $20,000) to suspend delisting pending panel decision

Cooperation Agreement (Form 6-K, May 16, 2025)

• Parties: Bon Nat Life Ltd (App-Chem) and Beijing Huahai Keyuan Technology Co., Ltd.
• Term: 36 months starting April 15, 2025
• Guaranteed Sales: USD 32 million minimum
• Scope: Exclusive distribution of postbiotic health products, including a patented hypoglycemic ingredient
• Key Clauses: Quality compliance, advance payments, and dispute resolution under Chinese courts

4. Financial and Strategic Analysis

Stock Performance (as of May 22, 2025)

Metric	Value
Price	$2.4890
Daily Change	+77.79%
Volume	22,260,654
52-Week Range	$1.14 – $82.75
Market Capitalization	$9.32 million
Average Volume (20-day)	2,038,431

Key Financial Ratios (TTM)

Ratio	Value
P/E	0.58
EPS	4.25
Price/Sales	0.01
Price/Book	0.12
Profit Margin	1.67%
Return on Assets	2.16%
Return on Equity	0.91%
Revenue	$23.84 M
Net Income	$0.42 M
Total Cash	$0.08 M
Debt/Equity	17.01%
Levered Free Cash Flow	-$8.58 M

Strategic Highlights

• Sales Platform: Exclusive partnership with Beijing Huahai Keyuan to leverage dedicated sales channels in China
• Product Focus: Postbiotic health ingredients, including patented glucose-regulating compounds
• Governance Actions: Share consolidation and expanded authorized capital to facilitate institutional investment and future financings

5. Market Position and Industry Context

• Sector: Natural ingredients, health & personal care
• Competitors: Other small-cap botanical extract and nutraceutical firms
• Liquidity Profile:
  • Beta (5Y Monthly): -0.48
  • Bid/Ask Spread indicative of limited trading depth
• Industry Trends:
  • Increasing demand for plant-derived functional ingredients
  • Regulatory emphasis on quality certifications (ISO 9001, ISO 22000, US FDA compliance)
• Challenges:
  • Nasdaq listing compliance
  • Working capital given low cash on hand and negative free cash flow

6. TL;DR

• On May 22, 2025, BON shares surged 77.79% to $2.4890 on heavy volume (22.3 million).
• April 15, 2025: Shareholders approved a 1-for-25 reverse split and boosted authorized shares.
• May 1, 2025: Nasdaq initiated delisting procedures; Bon Nat Life requested a hearing by May 6, 2025.
• May 16, 2025: Signed a 36-month, USD 32 million sales guarantee with Beijing Huahai Keyuan for postbiotic products.
• Future developments will depend on the outcome of the hearing, the implementation of the partnership in China, and improvements in trading liquidity.